Sign in
CompletedPhase 4

Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia

Key facts

Who runs it
Beni-Suef University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
240 people enrolled
Ended
1 Jan 2026
Type of study
Interventional, 6 groups
Treatments tested
  • Tamsulosin
  • Tadalafil
  • 5-Alpha Reductase Inhibitor
Record updated
20 July 2026

Who can take part

Age
50 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Male participants aged 50 years or older
  • Newly diagnosed with benign prostatic hyperplasia (BPH)
  • Moderate to severe lower urinary tract symptoms (LUTS), defined as International Prostate Symptom Score (IPSS) > 7
  • Prostate volume >40 mL confirmed by transrectal ultrasonography (TRUS)
  • Sexually active with a baseline International Index of Erectile Function-Erectile Function (IIEF-EF) score >10
  • Prostate-specific antigen (PSA) <4 ng/mL and no suspicious findings on digital rectal examination (DRE)
  • Able and willing to provide written informed consent

Who cannot take part

  • Previous prostate surgery
  • Current use of medications known to significantly affect sexual function
  • Concurrent use of nitrates or contraindicated antihypertensive medications
  • History of prostate cancer
  • Abnormal digital rectal examination suggestive of malignancy
  • Uncontrolled diabetes mellitus
  • Uncontrolled cardiovascular disease
  • Neurological disorders affecting bladder function
  • Renal impairment
  • Hepatic impairment
  • Active urinary tract infection
  • Known hypersensitivity to tamsulosin, tadalafil, or 5-alpha reductase inhibitors
  • Severe erectile dysfunction (IIEF-EF score ≤10)
  • Bladder stones or other significant urological pathology
  • Patients actively seeking fertility treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Benign prostatic hyperplasia (BPH) is a common condition among aging men that causes lower urinary tract symptoms (LUTS) and may negatively affect sexual function. This randomized single-blind controlled clinical trial compares the efficacy, safety, and sexual outcomes of different dosing regimens of tadalafil or tamsulosin combined with 5-alpha reductase inhibitors (5ARIs) in men with BPH and enlarged prostate volume. A total of 240 participants were randomly assigned to six treatment groups and followed for 12 weeks. Changes in urinary symptoms, erectile function, ejaculatory function, prostate volume, prostate-specific antigen (PSA), urinary flow rate, post-void residual volume, and adverse events were evaluated to determine the optimal combination regimen.

The 6 groups in the trial

  • Tamsulosin daily + 5ARI dailyTreatment being tested

    Participants received tamsulosin 0.4 mg once daily in combination with a 5-alpha reductase inhibitor administered once daily for 12 weeks.

    Treatment: Tamsulosin and 5-Alpha Reductase Inhibitor

  • Tamsulosin daily + 5ARI every other dayTreatment being tested

    Participants received tamsulosin 0.4 mg once daily combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.

    Treatment: Tamsulosin and 5-Alpha Reductase Inhibitor

  • Tamsulosin every other day + 5ARI every other dayTreatment being tested

    Participants received tamsulosin 0.4 mg every other day combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.

    Treatment: Tamsulosin and 5-Alpha Reductase Inhibitor

  • Tadalafil daily + 5ARI dailyTreatment being tested

    Participants received tadalafil 5 mg once daily in combination with a 5-alpha reductase inhibitor administered once daily for 12 weeks.

    Treatment: Tadalafil and 5-Alpha Reductase Inhibitor

  • Tadalafil daily + 5ARI every other dayTreatment being tested

    Participants received tadalafil 5 mg once daily combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.

    Treatment: Tadalafil and 5-Alpha Reductase Inhibitor

  • Tadalafil every other day + 5ARI every other dayTreatment being tested

    Participants received tadalafil 5 mg every other day combined with a 5-alpha reductase inhibitor administered every other day for 12 weeks.

    Treatment: Tadalafil and 5-Alpha Reductase Inhibitor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
"Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia: A Comparative Clinical Trial Study"
Record updated
20 July 2026